HSBC Holdings
SNDX icon

HSBC Holdings’s Syndax Pharmaceuticals SNDX Stock Holding History

HSBC Holdings’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$457K Sell
20,539
-2,922
-12% -$60.8K ﹤0.01% 2325
2026
Q1 		$556K Buy
23,461
+730
+3% +$15.9K ﹤0.01% 2179
2025
Q4 		$482K Sell
22,731
-33,793
-60% -$590K ﹤0.01% 2337
2025
Q3 		$884K Sell
56,524
-50,263
-47% -$658K ﹤0.01% 1847
2025
Q2 		$966K Buy
106,787
+56,512
+112% +$622K ﹤0.01% 1822
2025
Q1 		$613K Sell
50,275
-472
-0.9% -$6.66K ﹤0.01% 1984
2024
Q4 		$656K Buy
50,747
+6,741
+15% +$115K ﹤0.01% 2019
2024
Q3 		$852K Buy
44,006
+409
+0.9% +$8.45K ﹤0.01% 1768
2024
Q2 		$884K Buy
43,597
+4,006
+10% +$83.8K ﹤0.01% 1729
2024
Q1 		$942K Sell
39,591
-9,127
-19% -$204K ﹤0.01% 1803
2023
Q4 		$1.05M Buy
+48,718
New +$749K ﹤0.01% 1740

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

HSBC Holdings's SNDX Position: Q2 2026 in Review

HSBC Holdings reduced its Syndax Pharmaceuticals (SNDX) stake by 12% in Q2 2026, selling an estimated $60.8K and leaving 20,539 shares worth $457K. The position accounts for ﹤0.01% of the portfolio, ranked #2325.

HSBC Holdings first reported a position in SNDX in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.05M in Q4 2023. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • HSBC Holdings held 20,539 shares of Syndax Pharmaceuticals worth $457K as of Q2 2026.
  • HSBC Holdings sold 2,922 Syndax Pharmaceuticals shares in Q2 2026, an estimated $60.8K.
  • Syndax Pharmaceuticals made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2325 holding.
  • HSBC Holdings first reported a position in Syndax Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • HSBC Holdings's Syndax Pharmaceuticals position peaked at $1.05M in Q4 2023.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.